Compare IAC/Interactivecorp (PPLI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Vertex Pharmaceuticals Incorporated — how do they compare? IAC/Interactivecorp trades at $40.99 (market cap $3.05B), while Vertex Pharmaceuticals Incorporated trades at $507.41 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 41.8× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is more actively traded (931,019 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PPLI | VRTX | |
|---|---|---|
Market Cap | $3.05B | $127.55B |
Volume | 931,019 | 1,487,944 |
Sector | Media | Health |
52-Week High | $47.62 | $557.96 |
52-Week Low | $31.52 | $407.37 |
Typical Hold Time | 79 Days | 120 Days |
Enterprise Value | $3.53B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.94, up 0.86% with bullish technical signals and strong analyst support (71% buy ratings). The stock shows mixed fundamentals with a low P/E of 6.92 and P/B of 0.6, but recent earnings volatility includes two misses and one beat. Recent MGM takeover speculation has driven significant price movement, with shares surging 11.3% following acquisition discussions.
Investment outlook balances attractive valuation metrics against operational challenges. The company faces revenue decline from $5.2B (2022) to $2.4B (2025) and negative net income in 2025, though 2026 projections show recovery. Key risks include media industry headwinds and execution uncertainty, while MGM deal potential offers upside catalyst.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
